AT
Albatroz Therapeutics develops first-in-class antibodies targeting a novel component of the extracellular matrix. This approach addresses significant challenges in human health by focusing on the integrity of this biological structure. The company's initial therapeutic focus areas include oncology and inflammatory diseases.
Updated 20 months ago
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
OBSC
Funding rounds are not available yet.
Founders
Product
Features
- Albatroz Therapeutics develops first-in-class antibodies targeting a novel component of the extracellular matrix. This approach addresses significant challenges in human health by focusing on the integrity of this biological structure. The company's initial therapeutic focus areas include oncology and inflammatory diseases.